相关实验视频

Updated: Jun 27, 2025

The Forced Swim Test as a Model of Depressive-like Behavior

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

在治疗抑郁症时使用埃斯基塔洛普拉姆后,改变的血清素1B受体结合与治疗效果相关

M Gärde¹, G J Matheson^2,1, K Varnäs¹

¹Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.

The international journal of neuropsychopharmacology

|May 2, 2024

概括

选择性血清素再吸收抑制剂 (SSRI) 降低了重度抑郁症患者的大脑干中血清素1B (5-HT1B) 受体的结合. 这种减少与改善的抑郁症状相关,这表明5-HT1B结合作为治疗应答标志物.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
药理学药理学是指药理学的学科.

背景情况:

重度抑郁症 (MDD) 常常被选择性血清素再吸收抑制剂 (SSRI) 治疗.
针对血清素载体 (5-HTT) 的SSRI的精确抗抑郁机制尚不清楚.
血清素1B (5-HT1B) 受体与5-HTT相关,研究表明SSRI管理后动物模型中的受体结合或mRNA减少.

研究的目的:

在接受SSRI治疗的MDD患者中,研究脑5-HT1B受体结合的体内变化.
为了将这些变化与治疗疗效相关联.

主要方法:

一个正电子发射断层扫描 (PET) 研究在8名未经药物治疗的MDD患者中进行.
患者接受了PET扫描,使用5-HT1B无线电配体[11C]AZ10419369在每日ESCITALOPRAM治疗前和后3-4周.
抑郁症的严重程度使用蒙哥马利-阿斯伯格抑郁症评分表 (MADRS) 进行评估.

主要成果:

在埃斯基塔洛普拉姆治疗后,在脊脑干 (DBS) 区域观察到[11C]AZ10419369结合的显著减少,该区域包括中枢和脊髓核.
DBS [11C]AZ10419369结合的减少与治疗3-4周和6-7周的MADRS得分减少有很强的相关性.

结论:

这些发现支持先前的动物研究,这些研究表明,在使用SSRI后,RAPHE核中的5-HT1B受体结合减少.
脊脑干5-HT1B受体结合的变化可能成为MDD中SSRI治疗反应的潜在生物标志物.

关键词:

在5-HT1B受体上.定子发射断层扫描 (PET) 是一种定子发射断层扫描.这是一个SSRI.大型抑郁症主要是抑郁症.

更多相关视频

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

相关概念视频

G-protein Coupled Receptors

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...